Adavosertib

Generic Name: Adavosertib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Background: MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Clinical Trials

Adavosertib and Gemcitabine in Advanced Pancreatic

Phase 2

Withdrawn

Conditions: Pancreatic Cancer

Interventions: Drug: Adavosertib
Drug: Gemcitabine

First Posted Date: 2022-01-27

Last Posted Date: 2022-06-14

Lead Sponsor: James Cleary, MD, PhD

Registration Number: NCT05212025

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Phase 1

Terminated

Conditions: Advanced Solid Tumours

Interventions: Drug: Adavosertib
Drug: Rifampicin
Drug: Itraconazole
Drug: Omeprazole

First Posted Date: 2021-07-13

Last Posted Date: 2022-09-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 5

Registration Number: NCT04959266

Locations: 🇪🇸
Research Site, Malaga, Spain

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Phase 1

Terminated

Conditions: Advanced Solid Tumours

Interventions: Drug: Adavosertib

First Posted Date: 2021-07-02

Last Posted Date: 2022-09-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 3

Registration Number: NCT04949425

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Phase 2

Completed

Conditions: Uterine Serous Carcinoma

Interventions: Drug: Adavosertib

First Posted Date: 2020-10-19

Last Posted Date: 2023-08-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 109

Registration Number: NCT04590248

Locations: 🇪🇸
Research Site, Pozuelo de Alarcón, Spain

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase 1

Active, not recruiting

Conditions: Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Distal Esophagus Adenocarcinoma
Metastatic Esophageal Adenocarcinoma
Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8

Interventions: Drug: Adavosertib
Radiation: Radiation Therapy

First Posted Date: 2020-07-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT04460937

Locations: 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 4 locations

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Adavosertib (AZD1775)

First Posted Date: 2020-07-08

Last Posted Date: 2022-07-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT04462952

Locations: 🇯🇵
Research Site, Chuo-ku, Japan

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma
Advanced Malignant Solid Neoplasm

Interventions: Drug: Adavosertib

First Posted Date: 2020-06-19

Last Posted Date: 2025-05-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT04439227

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm